紫杉醇联合奈达铂或顺铂同步放化治疗中晚期食管鳞癌的近期疗效比较  

Comparison of the Recent Efficacy of Taxol Combined with Nedaplatin or Cisplatin in Synchronous Radiotherapy for Medium-advanced Esophageal Squamous Carcinoma

作　　者：蒋健 朱惠平 黄一帆 左云[1] JIANG Jian;ZHU Huiping;HUANG Yifan;ZUO Yun(Department of Oncology,Zhangjiagang Hospital Affiliated to Soochow University,Zhangjiagang,Jiangsu Province,215600 China)

机构地区：[1]苏州大学附属张家港医院肿瘤科,江苏张家港215600

出　　处：《系统医学》2023年第2期161-164,共4页Systems Medicine

基　　金：张家港市科技支撑计划(社会发展)(ZKS1816)。

摘　　要：目的分析中晚期食管鳞癌以紫杉醇联合奈达铂或顺铂进行同步放化疗治疗的近期疗效及安全性。方法回顾性分析2016年5月—2021年5月期间在苏州大学附属张家港医院确诊治疗的60例中晚期食管鳞癌患者,根据治疗方案的不同分为对照组与研究组,每组30例。在放疗期间,对照组采用紫杉醇+顺铂化疗,研究组采用紫杉醇+奈达铂化疗。对比两组疾病控制率、生活质量评分、不良反应发生率。结果研究组的疾病控制率略高于对照组高,差异无统计学意义(P>0.05)。治疗后,研究组精神健康、躯体疼痛、物质生活及生理功能评分分别为(81.64±3.38)分、(78.16±5.14)分、(81.31±3.79)分、(81.94±3.67)分,均高于对照组,差异有统计学意义(t=7.411、4.240、5.593、5.446,P<0.05)。对照组不良反应发生率高于研究组,差异有统计学意义(P<0.05)。结论中晚期食管鳞癌患者在同步放化疗中予以紫杉醇联合奈达铂或顺铂的近期疗效无显著差异,但紫杉醇联合奈达铂对患者生活质量的影响较小,不良反应更少。Objective To analyze the recent efficacy and safety of simultaneous radiotherapy with taxol combined with nedaplatin or cisplatin in the treatment of intermediate and advanced esophageal squamous carcinoma.Methods Sixty patients with advanced esophageal squamous cell carcinoma diagnosed and treated in Zhangjiagang Hospital Affiliated to Soochow University from May 2016 to May 2021 were retrospectively analyzed.According to the different treatment plans,the patients were divided into control versus study group groups with 30 cases in each group.During radiotherapy,the control group received paclitaxel+cisplatin chemotherapy and the study group received paclitaxel+Nedaplatin chemotherapy.Compare the disease control rate,quality of life score,and incidence of adverse reactions between the two groups.Results The disease control rate of the study group was slightly higher than that of the control group,and the difference was not statistically significant(P>0.05).After treatment,the scores of mental health,physical pain,material life and physiological function of the study group were(81.64±3.38)points,(78.16±5.14)points,(81.31±3.79)points and(81.94±3.67)points,respectively,which were higher than those of the control group,the difference was statistically significant(t=7.411,4.240,5.593,5.446,P<0.05).The incidence of adverse reactions in control group was higher than that in study group,and the difference was statistically significant(P<0.05).Conclusion There was no significant difference in the recent efficacy of taxol combined with nedaplatin or cisplatin in patients with intermediate to advanced esophageal squamous carcinoma treated with concurrent radiotherapy,but patients with taxol combined with nedaplatin had better improvement in quality of life and tolerable adverse effects.

关 键 词：中晚期食管鳞癌 同步放化疗 紫杉醇 奈达铂 顺铂 

分 类 号：R735[医药卫生—肿瘤]